REVIEW ARTICLE

Journal of Public Health, Policy, and Society (JPHPS)
DOI: https://doi.org/10.54117/e8ndpt77

1(1): 25-28 (2025)

Liability for Microbial Contamination: Legal Implications for Industry and Healthcare

Nwakoby, I. P.[1*], Iheukwumere, I. H.[2*], Iheukwumere, C. M.[3], Nwakoby, N. E.[2], Idigo, M. A.[4] and Ike, V. E.[5]

[1]Department of Private and Public Law, Faculty of Law, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.
[2]Department of Microbiology, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.
[3]Department of Applied Microbiology & Brewing, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.
[4]Department of Biological Sciences, Faculty of Natural Science, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.
[5]Department of Microbiology, University of Agriculture and Environmental Sciences, Umuagwo, Imo State, Nigeria.
*Corresponding author e-mail address: ip.nwakoby@coou.edu.ng / ik.iheukwumere@coou.edu.ng

Received: *26 Sept 2025* ***Accepted:*** *15 Oct 2025* ***Published :*** *19 Oct 2025*

ABSTRACT

Microbial contamination represents a persistent and critical threat to public health, economic stability, and consumer trust. This comprehensive review examines the complex legal landscape of liability arising from microbial contamination across two primary sectors: industry (encompassing pharmaceuticals, medical devices, food and beverage, and cosmetics) and healthcare (focusing on hospital-acquired infections and biocontainment failures). The analysis delves into the foundational legal theories underpinning liability, including negligence, strict liability, breach of warranty, and failure to warn. It explores the distinct regulatory frameworks governing each sector, such as the Food, Drug, and Cosmetic Act (FDCA) enforced by the FDA and the Centers for Medicare and Medicaid Services (CMS) conditions of participation for healthcare facilities. Significant case law is analyzed to illustrate how courts adjudicate claims of injury or damage caused by contaminants like bacteria, viruses, fungi, and endotoxins. The review further identifies key challenges in establishing causation and fault, particularly in environments with immunocompromised individuals or complex supply chains. Finally, the paper discusses proactive risk management strategies, including adherence to Good Manufacturing Practices (GMP), robust Quality Assurance/Quality Control (QA/QC) protocols, and comprehensive sterilization and environmental monitoring programs, as essential measures for mitigating legal exposure. This review concludes that in an era of increasing regulatory scrutiny and consumer awareness, a robust, science-based approach to contamination control is not merely a operational necessity but a fundamental legal defense.

How to cite this article
Nwakoby, I. P., Iheukwumere, I. H., Iheukwumere, C. M., Nwakoby, N. E., Idigo, M. A., & Ike, V. E. (2025). Liability for microbial contamination: Legal implications for industry and healthcare. *Journal of Public Health, Policy, and Society*, *1*(1), 25–28. https://doi.org/10.54117/e8ndpt77

Keywords
Microbial Contamination, Product Liability, Medical Negligence, Strict Liability, FDA Regulations, Healthcare-Associated Infections (HAIs), Good Manufacturing Practice (GMP), Causation, Duty of Care, Bioburden.

1.0 INTRODUCTION

Microbial contamination—the unintended introduction of bacteria, viruses, fungi, yeasts, or their byproducts (e.g., endotoxins)—into products, environments, or patients is a paramount concern in modern society (Iheukwumere *et al*., 2025a; Iheukwumere *et al*., 2025b). Its consequences range from minor product spoilage to severe illness, permanent disability, and death. High-profile outbreaks, such as those involving *Listeria* in processed foods, fungal meningitis from contaminated corticosteroids, and fatal bacterial infections linked to endoscopes, have catapulted this issue from a technical challenge into a subject of intense legal and regulatory scrutiny (Gould, 2013; Schaefer and Leffler, 2016; Iheukwumere *et al*., 2025c; Iheukwumere *et al*., 2025d).

The legal implications of such contamination are vast and multifaceted. Liability is not a monolithic concept but a web of intersecting legal theories, regulatory standards, and jurisdictional nuances. For industrial manufacturers, a contamination event can trigger lawsuits from injured consumers, regulatory actions including product seizures and injunctions, and criminal charges for executives in cases of proven fraud or gross negligence. For healthcare providers and institutions, contamination leading to healthcare-associated infections (HAIs) can result in massive medical malpractice claims, loss of accreditation, and non-reimbursement from insurers and government payers (Kracalik *et al*., 2020; Iheukwumere *et al*., 2025e; Iheukwumere *et al*., 2025f).

This paper provides a comprehensive 8-page review of the legal liability framework for microbial contamination. It is structured to first establish the foundational legal doctrines applicable across sectors. It then bifurcates the analysis to address the specific contexts of industry, and healthcare, detailing relevant regulations, case studies, and unique liability challenges. It also offers a comparative analysis and discusses the critical element of causation. Finally, it outlines essential risk mitigation and defense strategies before concluding with future directions.

2.0 FOUNDATIONAL LEGAL THEORIES OF LIABILITY

Liability for harm caused by microbial contamination is typically pursued under several established legal theories.

2.1 Negligence

Negligence is the most common theory used in contamination cases. To prevail, a plaintiff must prove four elements:

1. Duty of Care: The defendant owed a legal duty to the plaintiff to exercise reasonable care. Manufacturers have a duty to produce safe products; hospitals have a duty to provide a safe environmen.
2. Breach of Duty: The defendant failed to conform to the required standard of care. This is often shown by demonstrating a deviation from established industry standards, such as violating Good Manufacturing Practices (GMPs) or clinical hygiene protocols (e.g., handwashing).

3. Causation: The defendant's breach actually and proximately caused the plaintiff's injury. This is often the most difficult element to prove, as it requires linking a specific microbe from a specific source to a specific patient.
4. Damages: The plaintiff suffered actual, quantifiable harm (e.g., medical bills, lost wages, pain and suffering).

2.2 Strict Liability

In product liability cases, most jurisdictions apply the doctrine of strict liability (Restatement (Second) of Torts § 402A). Under this theory, a manufacturer or seller of a product is liable for harm caused by a defect in the product, even if they exercised all possible care. For a contamination claim, the plaintiff must prove:

The product was in a "defective condition" and "unreasonably dangerous."

The defect existed at the time the product left the defendant's control.

The defect caused the plaintiff's injury.

A sterile drug contaminated with *Pseudomonas aeruginosa* is inherently defective and unreasonably dangerous, making strict liability a powerful tool for plaintiffs (Voss Black and Decker, 1983; Iheukwumere *et al*., 2025g; Iheukwumere *et al*., 2025h; Iheukwumere *et al*., 2025i).

2.3 Breach of Warranty

This theory arises from contract law. Warranties can be express (a specific promise or description about the product, e.g., "sterile") or implied (a guarantee that the product is merchantable and fit for its ordinary purpose). A contaminated product plainly breaches both express warranties of sterility and the implied warranty of merchantability (Iheukwumere *et al*., 2025j; Iheukwumere *et al*., 2025k).

2.4 Failure to Warn (Marketing Defect)

A product can be flawlessly manufactured but still be deemed legally defective if it lacks adequate instructions or warnings of foreseeable risks. This is crucial for products that are not terminally sterilized and require aseptic handling by the end-user (e.g., a healthcare professional reconstituting a lyophilized drug). Failure to provide clear instructions on handling to prevent contamination can create liability.

3.0 LIABILITY IN THE INDUSTRIAL SECTOR

The industrial sector is governed by a dense framework of federal regulations that effectively set the standard of care for negligence claims.

3.1 Pharmaceuticals and Biologics

The U.S. Food and Drug Administration (FDA) mandates strict adherence to Current Good Manufacturing Practices (cGMP) under the FDCA. Contamination events can lead to:

- **Product Recalls:** Class I recalls for contamination with a reasonable probability of causing serious adverse health consequences.
- **Warning Letters and Injunctions:** FDA enforcement actions that can halt production.
- **Liability Lawsuits:** Multidistrict litigation (MDL) is common when a contaminated drug injures many patients across the country.

Case Study: The New England Compounding Center (NECC) Tragedy. In 2012, contaminated methylprednisolone acetate injections produced by NECC caused a nationwide fungal meningitis outbreak, resulting in over 100 deaths and 700+ cases of infection (Iheukwumere *et al*., 2025l; Ekechukwu *et al*., 2025a; Ekechukwu *et al*., 2025b; Ekechukwu *et al*., 2025c). The ensuing legal fallout was catastrophic. The company filed for bankruptcy, multiple executives and pharmacists were convicted on criminal charges including racketeering and murder, and a $200 million settlement fund was established for victims (Smith *et al*., 2015; Dim *et al*., 2025a; Dim *et al*., 2025b). This case exemplifies the convergence of civil liability (negligence, strict liability), regulatory failure, and criminal liability for gross disregard of safety standards.

3.2 Medical Devices

The FDA regulates devices, with sterility being a fundamental requirement for any invasive or implantable device (Class II and III). Liability can arise from:

- Manufacturing Flaws: A breach in packaging integrity, inadequate sterilization validation, or poor environmental controls during assembly.
- Design Defects: A device design that is inherently difficult to clean or sterilize between uses (e.g., complex duodenoscopes with microscopic crevices) (FDA, 2019).
- Failure to Warn: Inadequate reprocessing instructions for reusable devices.

3.3 Food and Beverage

The food industry is regulated by the FDA and the USDA. Liability often stems from pathogens like *Salmonella*, *Listeria*, and *E. coli* O157:H7 (Dim *et al*., 2025c; Ike *et al*., 2025a; Ike *et al*., 2025b).

The Food Safety Modernization Act (FSMA): Shifts the focus from responding to contamination to preventing it. FSMA's Preventive Controls rules mandate hazard analysis and risk-based preventive controls, making a failure to implement these controls strong evidence of negligence (Ike *et al*., 2025c; Ike *et al*., 2025d).

Strict Liability: Is routinely applied to contaminated food products.

3.4 Cosmetics and Personal Care Products

While less stringently regulated than drugs, cosmetics must not be "adulterated" under the FDCA. Microbial contamination, especially by organisms like *Pseudomonas aeruginosa*, can cause severe eye and skin infections, leading to product liability suits based on negligence and strict liability (Ike *et al*., 2025e; Ugwu *et al*., 2025a; Ugwu *et al*., 2025b).

4.0 LIABILITY IN THE HEALTHCARE SECTOR

Liability in healthcare focuses on the standard of care provided to patients within the facility.

4.1 Healthcare-Associated Infections (HAIs)

HAIs, such as surgical site infections (SSIs) or central line-associated bloodstream infections (CLABSIs), are a major cause of morbidity and mortality. While not all HAIs are preventable, a plaintiff can allege negligence if:

- The infection rate is significantly higher than the national benchmark.

- The facility failed to follow its own infection control policies or nationally accepted guidelines (e.g., from CDC or professional societies).
- There was a failure in environmental hygiene (e.g., improper cleaning of rooms and equipment).
- Healthcare workers failed to adhere to basic aseptic techniques (Moneymaker and Cawley, 2021).

4.2 Biocontainment and Laboratory Safety

Laboratories ha ndling infectious agents have a duty to protect both their workers and the public. A release of a pathogen due to inadequate safety protocols (BSL-3/4 practices), faulty equipment, or insufficient training can lead to:

Worker's compensation claims from infected employees.

Negligence claims from third parties allegedly infected due to the release.

Significant regulatory penalties from OSHA and the CDC.

5.0 COMPARATIVE ANALYSIS AND THE CAUSATION HURDLE

A central challenge unifying all microbial contamination litigation is proving causation. Unlike a mechanical defect in a car, microbes are ubiquitous (Amadi *et al*., 2017). A plaintiff must use epidemiological evidence, microbial genotyping (e.g., whole-genome sequencing), and expert testimony to establish that the specific pathogen that caused their injury originated from the defendant's product or facility and not from another source (e.g., the community) (Nwike *et al*., 2017; Ekesiobi *et al*., 2025). This requires sophisticated scientific evidence and is often the point on which cases are won or lost (Daubert, 1993).

The standard of care in industry is often clearly defined by cGMPs and FDA regulations, making it easier to prove a breach of duty. In healthcare, the standard of care is more fluid, defined by evolving clinical guidelines and institutional policies, making expert testimony from other healthcare professionals absolutely critical.

6.0 RISK MITIGATION AND LEGAL DEFENSE STRATEGIES

The best legal defense is a proactive, prevention-oriented culture. Key strategies include:

- ✓ Robust Quality Management System (QMS): Implementing and meticulously documenting a QMS based on ISO 13485 (devices) or cGMP (drugs).
- ✓ Comprehensive Environmental Monitoring (EM): Routine testing of air, surfaces, and water in cleanrooms and healthcare environments to identify trends and prevent outbreaks.
- ✓ Sterilization Validation: Ensuring sterilization processes are rigorously validated and periodically re-validated.
- ✓ Supplier Control: Qualifying and auditing suppliers of raw materials and components.
- ✓ Thorough Documentation and Investigation: All deviations, non-conformances, and corrective and preventive actions (CAPA) must be thoroughly documented. This documentation is discoverable in litigation and can be used to demonstrate a culture of quality and continuous improvement.
- ✓ Adequate Labeling and Instructions for Use: Clear, unambiguous instructions for handling, storage, and use to mitigate failure-to-warn claims.
- ✓ Infection Control Programs: In healthcare, a robust, data-driven infection prevention and control program is the primary shield against HAI liability claims.

7.0 CONCLUSION

Liability for microbial contamination is a grave and expanding area of law that intersects with science, medicine, and public policy. The legal doctrines of negligence and strict liability provide avenues for injured parties to seek compensation, while a thicket of regulations sets the minimum standards for industry and healthcare providers. The NECC tragedy stands as a stark reminder that egregious failures can lead not only to civil liability but also to criminal prosecution.

The evolving landscape, marked by advances in microbial forensics and increased regulatory power under statutes like FSMA, is raising the standard of care. For corporations and healthcare institutions alike, investing in a sophisticated, well-documented, and proactive contamination control strategy is no longer optional. It is a fundamental ethical obligation and the most critical investment in risk management and legal defense they can make. Ultimately, in the court of law and the court of public opinion, the ability to demonstrate a unwavering commitment to quality and safety is the strongest possible defense against the devastating consequences of microbial contamination.

REFERENCES

Amadi, R.E., Iheukwumere, I.H. and Unaeze, B.C. (2017). Effects Of Crude Alkaloid Extracted From Ocimum Gratissimum On The Activity Of Ciprofloxacin Against Salmonella Enterica Serovar Typhi. *Advances in Life Science and Technology* 58.

Daubert v. Merrell Dow Pharms., Inc.509 U.S. 579 (1993).

Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, . J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025a). Multiple Antibiotic Resistance Bacterial Strains in Frozen Meat Sold at Abagana, Anambra State: A Public Health Concern. *IPS Journal of Applied Microbiology and Biotechnology*, *4*(3), 181–186. https://doi.org/10.54117/ijamb.v4i3.75

Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025b). The Burden of Antibiotic Resistance: Evaluating the Impact of Multiple Antibiotic-Resistant Enteric Bacteria in Academic Environments. *IPS Interdisciplinary Journal of Biological Sciences*, *4*(4), 144–149. https://doi.org/10.54117/iijbs.v4i4.78

Dim, C. N., Iheukwumere, I. H., Iheukwumere, C. M., Ugwu, C. H., Ike, V. E., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025c). Antimicrobial resistance in aquaculture: evaluating pseudomonas aeruginosa from fish ponds. *IPS Intelligentsia Multidisciplinary Journal*, *4*(1), 32–36. https://doi.org/10.54117/iimj.v4i1.10

Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025a). Bacterial Loads of Smoked Fish and Chicken: Role of pH and Moisture Content. *IPS Applied Journal of Nutrition, Food and Metabolism Science*, 3(1), 44–49. https://doi.org/10.54117/iajnfms.v3i1.102.

Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025b). Biological Inhibition of Pathogenic Bacteria Isolated from Smoked Fish and Chicken: An In Vitro Study. IPS

Interdisciplinary Journal of Biological Sciences, 4(2), 85–92. https://doi.org/10.54117/iijbs.v4i2.50.

Ekechukwu, C. C., Umeh, S. O., Iheukwumere, I. H., & Iheukwumere, C. M. (2025c). Prophylactic Potential of the Most Potent Synergistic Biological Agent against Bacterial Infections from Smoked Fish and Chicken. IPS Journal of Applied Microbiology and Biotechnology, 4(2), 153–160. https://doi.org/10.54117/ijamb.v4i2.57.

Ekesiobi, A. O., Iheukwumere, C. M., Iheukwumere, I. H., Ejike, C. E., Ilechukwu, C. C., Ike, V. E., Okereke, F. O., & Ochibulu, S. C. (2025). Hyping the Inhibitory Activity of Xylopia aethiopica against Vibrio cholerae using Azithromycin. IPS Journal of Basic and Clinical Medicine, 2(3), 93–98. https://doi.org/10.54117/ijbcm.v2i3.16

Food and Drug Administration (FDA). (2019). The FDA Continues to Alert Health Care Professionals and Consumers that Duodenoscopes May Remain Contaminated with Deadly Bacteria After Reprocessing. FDA Safety Communication.

Gould, L. H. (2013). The legal implications of foodborne illness. Food Safety News

Iheukwumere, I. H., Ajeh, J. C., Iheukwumere, C. M., Ike, V. E., Obianom, A. O., Ihenatuoha, U. A. ., Igboanugo, E. U., Onwuasoanya, U. F., Okereke, F. O., Nnadozie, C. H., Agbaugo, C. F., Nwike, M. I., Nwakoby, N. E., & Ilechukwu, C. C. (2025l). Exploring the Phytochemical and Antimicrobial Properties of Fruit Vinegar: A Study on Phoenix Dactylifera and Malus Sylvestris. *IPS Journal of Applied Microbiology and Biotechnology*, 4(1), 115–122. https://doi.org/10.54117/ijamb.v4i1.48

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025a). *Lactobacillus* fermentation of chicken feather: Impact on structural development and immune system of albino Wistar rats. *IPS Applied Journal of Nutrition, Food and Metabolism Science*, *3*(2), 75–83. https://doi.org/10.54117/qabcj082

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025b). Evaluation of *Lactobacillus* fermented chicken feather meal on blood lipoproteins and lymphocyte count in rats. *IPS Journal of Nutrition and Food Science*, *4*(4), 569–577. https://doi.org/10.54117/012d8612

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025c). Exploring the impact of *Lactobacillus*-fermented chicken feather on organ weights and functions in albino Wistar rats. *IPS Journal of Toxicology*, *3*(3), 68–75. https://doi.org/10.54117/zc1h5865

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025d). Corollary of Lactobacillus Fermented Chicken Feather on Organ-Weight and Leukocyte Indices of Broiler Chicks. *IPS Intelligentsia Multidisciplinary Journal*, *4*(1): 46-53. https://doi.org/10.54117/iimj.v4i1.12

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025e). Fermented Chicken Feather Meal as a Potential Feed Supplement: Effects on Body Weight and Immune Function. *IPS Intelligentsia Multidisciplinary Journal*, *4*(1), 37–45. https://doi.org/10.54117/iimj.v4i1.11

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025f). Corollary of Lactobacillus Fermented Chicken Feather on Growth Performance of Rats. *IPS Journal of Biotechnology and Applied Biochemistry*, *1*(2), 57–65. https://doi.org/10.54117/ijbab.v1i2.85

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025g). Corollary of Lactobacillus Fermented Chicken Feather on Growth Performance of Rats. *IPS Journal of Biotechnology and Applied Biochemistry*, *1*(2), 57–65. https://doi.org/10.54117/ijbab.v1i2.85

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025h). Fermented Chicken Feather as a Sustainable Feed Ingredient: Effects on Broiler Chick Health and Growth. *IPS Interdisciplinary Journal of Biological Sciences*, *4*(4), 157–165. https://doi.org/10.54117/iijbs.v4i4.84

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025i). Assessment of Fermented Corn Mixed with Fish Meal as a Chicken Additive for Healthy Broiler Chicks. *Journal of Agriculture, Food Technology and Sustainability*, *2*(1), 60–68. https://doi.org/10.54117/jafts.v2i1.82

Iheukwumere, I. H., Iheukwumere, C. M., Idigo, M. A., & Ezekwueche, S. N. (2025j). Evaluation of Fermented Corn Residue as a Growth Promoter in Broiler Chicken Diets. *Journal of Agriculture, Food Technology and Sustainability*, *2*(1), 69–77. https://doi.org/10.54117/jafts.v2i1.83

Iheukwumere, I. H., Iheukwumere, C. M., Obianom, A. O., Nnadozie, C. H., Okereke, F. O., Onwuasoanya, U. F., … Destiny, E. C. (2025k). Cross-Sectional Study of Major Strains of Salmonella enterica Subspecies Enterica Serovar Typhi among Borehole Used in Uli Community. IPS Journal of Public Health, 5(2), 205–210. https://doi.org/10.54117/ijph.v5i2.40.

Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025a). Prevalence of Bacillus cereus in Powdered Soybean Sold in Uli Community, Anambra State: A Cross-Sectional Study. *IPS Journal of Basic and Clinical Medicine*, *2*(3), 108–114. https://doi.org/10.54117/ijbcm.v2i3.18

Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025b). *Bacillus cereus in Uli's cornflour: A prevalence study*. *IPS Journal of Nutrition and Food Science*, *4*(3), 544–548. https://doi.org/10.54117/8btte840

Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025c). Pathogenic Profile Analysis: In Vitro Screening of Enteric Bacteria from University Dusters. *IPS Journal of Applied Microbiology and Biotechnology*, *4*(3), 187–191. https://doi.org/10.54117/ijamb.v4i3.76

Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025d). Frozen Fish Pathogens: Antimicrobial Resistance and Public Health Implications. *IPS Interdisciplinary Journal of Biological Sciences*, *4*(4), 138–143. https://doi.org/10.54117/iijbs.v4i4.77

Ike, V. E., Iheukwumere, I. H., Iheukwumere, C. M., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., & Ochibulu, S. C. (2025e). Stream water quality assessment: Antibiotic resistance of Lac-positive enteric bacterial isolates. *Journal of Pollution Monitoring, Evaluation Studies and Control*, *4*(2), 120–125. https://doi.org/10.54117/jpmesc.v4i2.21.2025

Kracalik, I. (2020). Assessing the Attribution of Healthcare-Associated Infections to the Hospital Setting Using a Population-Based Approach. *Clinical Infectious Diseases* 71(5):105 – 111

Moneymaker, K. and Cawley, M. J. (2021). Legal and ethical considerations in healthcare-associated infections. *Journal of Pharmacy Practice* 34(1): 127 – 131.

Nwike, M.I., Iheukwumere, I.H. and Uneze, B.C. (2017). Effect of Spices, pH and Temperature on the Survival and Multiplication of Staphylococcus aureus in Locally Made Soya Milk Drink. *Journal of Natural Sciences Research* 7(4):1-9

Schaefer, M. K. and Leffler, D. A. (2016). The New England Compounding Center tragedy: A review of the legal and clinical aspects of a national disaster. *Journal of Law, Medicine and Ethics* 44(1): 167 – 171.

Smith, R. M. (2015). The Fungal Meningitis Outbreak: A Public Health Perspective. *Clinical Infectious Diseases* 60(2): 229 – 237.

Ugwu, C. H., Iheukwumere, I. H., Iheukwumere, C. M., Ike, V. E., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025a). Maternal health and antibiotic resistance: *Klebsiella pneumoniae* isolates analysis. *IPS Journal of Public Health*, *5*(3), 290–295. https://doi.org/10.54117/s3tx6v26

Ugwu, C. H., Iheukwumere, I. H., Iheukwumere, C. M., Ike, V. E., Dim, C. N., Ezendianefo, J. N., Egbe, P. A., Oragwu, I. P., Orji, C. C., Ogbonnaya, O. C., Onwuasoanya, U. F., Okereke, F. O., Oduenyi, P. M., & Ochibulu, S. C. (2025b). Ocimum gratissimum Extract's Effectiveness against Vibrio cholerae from Uli Streams. *IPS Journal of Phytochemistry and Medicinal Plant Research*, *1*(2), 15–19. https://doi.org/10.54117/ijpmpr.v1i2.38

Voss, v. Black and Decker Mfg. Co, 59 N.Y.2d 102, 450 N.E.2d 204 (1983).